FOXO4-DRI

What it is

Senescent cells have stopped dividing but do not die. They remain in the tissue, send out inflammatory signals and disturb their neighbors. They accumulate with age. Senolytics are substances intended to selectively eliminate precisely these cells.

FOXO4-DRI was developed at Erasmus University Rotterdam in the group led by Peter de Keizer and presented in 2017 in the journal Cell. The name describes the design: the peptide mimics a section of FOXO4 but is built in D-retro-inverso form, that is, from mirror-image amino acids in reverse order. This makes it hard for the body’s own enzymes to break down. An attached cell-penetrating peptide ensures that it gets into the cell.

How it works

In healthy cells, p53 is a guardian: if the genetic material is badly damaged, p53 initiates cell death. Senescent cells escape this fate because FOXO4 holds on to p53 in their nucleus and thus blocks the self-destruct program. FOXO4-DRI wedges itself in between, p53 is pushed out of the nucleus, and the senescent cell goes into apoptosis. Healthy cells capable of dividing hardly depend on this mechanism and are therefore largely spared.

In 2025 the same line of research elucidated the binding in detail. Nuclear magnetic resonance showed that both the FOXO4 part and the cell-penetrating peptide dock onto a flexible section of p53 and form a transiently folded complex. The principle of action is thus well understood at the molecular level, but so far only in the test tube and in animals.

What was shown in animal models

The original study worked with two mouse models: animals with a genetic defect that makes them age quickly, and naturally aged mice. In both, the peptide restored fitness, fur density and kidney function. In addition, it protected against organ damage from the chemotherapy drug doxorubicin, which drives cells into senescence on a massive scale.

Other groups have since tested the approach in further organs. In 2020 FOXO4-DRI alleviated age-related testosterone deficiency in old mice by removing aged Leydig cells in the testes; in 2024 better sperm quality and sperm production followed. In 2022 it slowed pulmonary fibrosis in a mouse model, similar to the approved drug pirfenidone. In 2025 it slowed aging of the aorta in old mice and improved vascular function.

The principle also works on human material. In cartilage cells from healthy donors that had been heavily expanded in the laboratory, FOXO4-DRI removed more than half of the cells, while fresh cells were hardly affected. In tissue from keloids, overgrown scars, it drove senescent connective tissue cells into cell death.

What users report

In the same year the Cell paper appeared, FOXO4-DRI turned up at peptide vendors. In May 2017 a vendor publicly documented a self-experiment and reported hair growth and a feeling of rejuvenation, without laboratory data. The longevity blog Fight Aging acknowledged the courage but noted that this was a single case with a conflict of interest and that hardly any meaningful measures had been collected.

In the Longecity community, a structured self-experiment with inflammatory markers, blood pressure, heart rate variability, pulse wave velocity and an epigenetic clock was designed in 2018. The author himself expected the effects in a healthy person around 50 to be too small to measure. No published results exist. We take such reports seriously, but they do not replace a study.

What the studies show

Baar et al. 2017 — the original study in Cell

Cell experiments and two mouse models, fast-aging and naturally aged animals. FOXO4-DRI selectively drove senescent cells into apoptosis, protected against doxorubicin damage and restored fitness, fur density and kidney function. Animal data, no use in humans.

Zhang et al. 2020 — testosterone in old age

Aged mice and a cell model for Leydig cells. The peptide removed senescent Leydig cells, improved the environment in the testes and alleviated age-related testosterone deficiency. In humans, FOXO4 was detected in Leydig cells; nobody was treated.

Huang et al. 2021 — human cartilage cells

Cartilage cells from healthy donors, expanded in the laboratory as for a cartilage transplant. FOXO4-DRI removed more than half of the heavily expanded cells and reduced senescence. Cartilage formation did not improve as a result, however; only the inflammatory signals in the new tissue decreased.

Bourgeois et al. 2025 — the binding in detail

Structural biology study using nuclear magnetic resonance. It shows how the peptide binds to p53 and that the binding becomes stronger when p53 is marked by cellular stress. A basis for further developed active substances.

Where the data stop

In humans there is nothing: no study on efficacy, none on tolerability, none on how long the peptide stays in the body or where it ends up. No trial with FOXO4-DRI is entered in the ClinicalTrials.gov registry. A structured review from 2026 states that the peptide has a senolytic effect preclinically but is not clinically validated, and names studies on pharmacokinetics, administration and long-term toxicology as prerequisites.

There is also a substantive point. In the human cartilage cells the senescence markers fell, but function did not improve. Fewer zombie cells therefore do not automatically mean younger tissue. Whether the mouse findings on fur, kidney or testosterone can be repeated in humans is open.

Status, approval and legal

FOXO4-DRI is not approved as a medicine in Germany, the EU or the US, and no clinical development is registered. It is sold as a research peptide on the gray market and in Germany is a medicine without approval. It is not named on the WADA Prohibited List 2026 or on the FDA list of substances with potential significant safety risks. We do not give dosage information for non-approved substances.

Safety

Safety data in humans do not exist. In the original study, the peptide was well tolerated by the mice under the chosen conditions, but that cannot be transferred to humans. The most delicate point is p53: the peptide interferes with the interplay of the cell’s most important tumor suppressor, and the 2026 review explicitly names testing of p53-dependent tumor surveillance as an open question. At the same time, FOXO4-DRI is currently being tested in cancer research as an agent against senescent tumor cells, so the direction is not clear-cut. It is also unknown whether the immune system reacts to the peptide. With gray-market products, there is moreover no assurance that the ampoule contains what the label says.

Sources

• Baar et al., Cell 2017
• Zhang et al., Aging 2020
• Huang et al., Frontiers in Bioengineering and Biotechnology 2021
• Han et al., Journal of Cellular and Molecular Medicine 2022
• Hu et al., Frontiers in Bioengineering and Biotechnology 2025
• Bourgeois et al., Nature Communications 2025
• Mateescu et al., Antioxidants 2026
• Fight Aging 2017 – self-experiment with FOXO4-DRI
• Longecity forum 2018 – plan for a self-experiment